Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 28

Sort by

Sort Order Select

Journal Articles

Impact of Obesity in Patients with Multiple Myeloma Receiving High-Dose Melphalan Followed By Autologous Hematopoietic Cell Transplantation

Justina Ofori Frimpong, PharmD, BCOP, Rebecca Tombleson, PharmD, BCOP, Melissa Alsina, Jamie Shapiro, PharmD, BCOP, Jongphil Kim, PhD, Binglin Yue, MS, Janelle Perkins, PharmD, BCOP, Taiga Nishihori, MD

Blood (2016) 128 (22): 4636.

https://doi.org/10.1182/blood.V128.22.4636.4636

Published: 2016

Journal Articles

An International Multicenter Comparative Analysis of Tacrolimus Plus Sirolimus with or without Antithymocyte Globulin As Graft-Versus-Host Disease Prophylaxis in HLA-Mismatched Allogeneic Hematopoietic Cell Transplantation

Mohamed A. Kharfan-Dabaja, MD, Rocio Parody, MD, Janelle Perkins, PharmD, Oriana Lopez-Godino, MD, Lucia Lopez-Corral, MD, Lourdes Vazquez, MD, Dolores Caballero, MD, Jose Falantes, MD, Jamie Shapiro, PharmD, Guillermo Orti, MD, Pere Barba, MD, David Valcárcel, MD PhD, Alber Esquirol, MD, Rodrigo Martino, MD PhD, Jose Luis Piñana, MD, Carlos Solano, MD, Joseph A Pidala, MD, PhD, Claudio Anasetti, MD, Jose A. Perez-Simon, MD, PhD

Blood (2015) 126 (23): 3142.

https://doi.org/10.1182/blood.V126.23.3142.3142

Published: 2015

Journal Articles

TP53 and IDH2 Somatic Mutations Are Associated with Poor Outcomes Following Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndrome

Mohamed A. Kharfan-Dabaja, MD, Rami S. Komrokji, MD, Qing Zhang, PhD, David Sallman, MD, Asmita Mishra, MD, Najla H. Al Ali, BDS, MSc, Taiga Nishihori, MD, Teresa Field, MD, PhD, Karma Z Salem, MD, Janelle Perkins, PharmD, Ling Zhang, MD, Lynn C. Moscinski, MD, Hugo F. Fernandez, MD, Jeffrey E Lancet, MD, Alan F. List, MD, Claudio Anasetti, MD, Eric Padron, MD

Blood (2015) 126 (23): 4382.

https://doi.org/10.1182/blood.V126.23.4382.4382

Published: 2015

Journal Articles

Allogeneic Hematopoietic Stem Cell Transplantation (HCT) for Acute Myeloid Leukemia (AML) Not in First Remission

Kendra L Sweet, MD MS, Jeffrey E Lancet, MD, Ryan Hillgruber, BS, Megan Melody, MS, Amina Llishi, Janelle Perkins, PharmD, Hugo F. Fernandez, MD, Teresa Field, MD, PhD

Blood (2015) 126 (23): 4388.

https://doi.org/10.1182/blood.V126.23.4388.4388

Published: 2015

Journal Articles

Sirolimus, Tacrolimus and Antithymocyte Globulin Are Associated with Improved Overall Survival When Compared to Methotrexate, Tacrolimus and Antithymocyte Globulin in Mismatched Unrelated Allogeneic Hematopoietic Cell Transplantation

Rebecca Nelson, PharmD, Janelle Perkins, PharmD, Jamie Shapiro, PharmD, Jongphil Kim, PhD, Binglin Yue, M.S., Claudio Anasetti, MD, Mohamed A Kharfan-Dabaja, MD

Blood (2014) 124 (21): 2553.

https://doi.org/10.1182/blood.V124.21.2553.2553

Published: 2014

Journal Articles

Utility Of Revised International Prognostic Scoring System (R-IPSS) To Predict Outcome Of Myelodysplastic Syndromes (MDS) Patients After Allogeneic Hematopoietic Stem Cell Transplantation (AHSCT)

Maria Gabriela Corrales-Yepez, MD, Teresa Field, MD, PhD, Alan List, MD, Claudio Anasetti, MD, Janelle Perkins, PharmD, Najla H Al Ali, Asmita Mishra, MD, Eric Padron, MD, Jeffrey E Lancet, MD, Mohamed A. Kharfan-Dabaja, MD, Rami S Komrokji, MD

Blood (2013) 122 (21): 5222.

https://doi.org/10.1182/blood.V122.21.5222.5222

Published: 2013

Journal Articles

Evaluation Of Allogeneic Hematopoietic Cell Transplantation (HCT) Outcomes Of One Hundred Thirty-Two Patients With Myelodysplastic Syndrome (MDS) Or Chronic Myelomonocytic Leukemia (CMML) Up To Age Seventy-Five and The Effect Of Pre-Transplant 5-Azacitidine

Teresa Field, MD, PhD, Janelle Perkins, PharmD, Marcie Tomblyn, MD, MS, Ryan Hillgruber, Taiga Nishihori, MD, Asmita Mishra, MD, Joseph Pidala, MD, MS, Ernesto Ayala, MD, Frederick L Locke, MD, Melissa Alsina, MD, Brian C. Betts, MD, Eric Padron, MD, Hugo F Fernandez, MD, Jeffrey E Lancet, MD, Alan List, MD, Rami S Komrokji, MD, Mohamed A. Kharfan-Dabaja, MD, Claudio Anasetti, MD

Blood (2013) 122 (21): 2152.

https://doi.org/10.1182/blood.V122.21.2152.2152

Published: 2013

Journal Articles

Survival Advantage of Cell Therapy Over Cytotoxic Therapy Alone in Adult Patients with Relapsed AML After Allogeneic Hematopoietic Stem Cell Transplantation

Ghada M Kunter, MD, Janelle Perkins, PharmD, Taiga Nishihori, MD, Frederick L Locke, MD, Teresa Field, MD, PhD, Hugo F Fernandez, MD

Blood (2012) 120 (21): 1994.

https://doi.org/10.1182/blood.V120.21.1994.1994

Published: 2012

Journal Articles

Mycophenolate Mofetil versus Methotrexate for Prevention of Acute Graft-Versus-Host Disease: Results of a Systematic Review Limited to Prosepective Randomized Controlled Studies

Mohamed A. Kharfan-Dabaja, MD, Rahul Mhaskar, MPH, PhD, Tea Reljic, Joseph Pidala, MD, MS, Janelle Perkins, PharmD, Benjamin Djulbegovic, MD, PhD, Ambuj Kumar, MD, MPH

Blood (2012) 120 (21): 4168.

https://doi.org/10.1182/blood.V120.21.4168.4168

Published: 2012

Journal Articles

Fludarabine and Targeted Busulfan Is Safe and Effective Conditioning Before Hematopoietic Stem Cell Transplantation in Adult Patients with Acute Lymphoblastic Leukemia in First Remission

Ghada M Kunter, MD, Janelle Perkins, PharmD, Lia Perez, MD, Joseph Pidala, MD, MS, Teresa Field, MD, PhD, Marcie Tomblyn, MD, MS, Hugo F. Fernandez, MD, Claudio Anasetti, MD

Blood (2011) 118 (21): 891.

https://doi.org/10.1182/blood.V118.21.891.891

Published: 2011

Journal Articles

Evaluation of a Risk-Based Algorithm for the Utilization of Plerixafor As Primary Mobilization of CD34+ Cells in Autologous Hematopoietic Cell Transplant Candidates,

Jamie Shapiro, PharmD, Janelle Perkins, PharmD, Ryan Bookout, PharmD, Rebecca Tombleson, PharmD, Ernesto Ayala, MD, William E. Janssen, PhD, Claudio Anasetti, MD, Hugo F. Fernandez, MD

Blood (2011) 118 (21): 4060.

https://doi.org/10.1182/blood.V118.21.4060.4060

Published: 2011

Journal Articles

Sirolimus/Tacrolimus Facilitates Preferential Recovery of Regulatory T Cells (Treg) After Allogeneic Hematopoietic Cell Transplantation (HCT), and Is More Effective Than Methotrexate/Tacrolimus in Preventing Grade II-IV Acute Graft Vs. Host Disease (GVHD) and Moderate to Severe Chronic Gvhd

Joseph Pidala, MD, MS, Jongphil Kim, PhD, Heather Jim, PhD, Hugo F. Fernandez, MD, Marcie Tomblyn, MD, MS, Mohamed A Kharfan-Dabaja, MD, Brian C. Betts, MD, Taiga Nishihori, MD, Mian Xu, William E. Janssen, PhD, Frederick L Locke, MD, Ernesto Ayala, MD, Lia Perez, MD, Janelle Perkins, PharmD, Teresa Field, MD, PhD, Leonel Ochoa, Melissa Alsina, MD, Claudio Anasetti, MD

Blood (2011) 118 (21): 323.

https://doi.org/10.1182/blood.V118.21.323.323

Published: 2011

Journal Articles

Phase II Study of a Novel Reduced Toxicity Preparative Regimen for Hematopoietic Cell Allografting Combining Pentostatin (Nipent) and Targeted Doses of Intravenous Busulfan (Busulfex) with or without Rituximab (PB±R) Using a Novel Principle of CD4-Guided Immune Suppression

Mohamed A Kharfan-Dabaja, MD, Claudio Anasetti, MD, Nathalie Luis, B.S., Linda Brand, R.N., Janelle Perkins, PharmD, Hugo F. Fernandez, MD, Jose Leonel Ochoa-Bayona, M.D., Taiga Nishihori, MD, Lia E Perez, MD, Ernesto Ayala, MD, Javier Pinilla-Ibarz, MD, PhD, Lubomir Sokol, MD, PhD, Joseph Pidala, MD, MS, Frederick L Locke, MD, Eduardo M. Sotomayor, Teresa Field, MD, PhD, Marcie Tomblyn, MD, MS

Blood (2011) 118 (21): 3022.

https://doi.org/10.1182/blood.V118.21.3022.3022

Published: 2011

Journal Articles

Azacitidine for Treatment of Therapy Related Myelodysplastic Syndrome

Rami S. Komrokji, MD, Najla H Al Ali, M.S, E Alrawi, MD, Eric Padron, MD, Janelle Perkins, PharmD, Teresa Field, MD, PhD, Jeffrey E. Lancet, MD, Alan F. List, MD

Blood (2011) 118 (21): 1712.

https://doi.org/10.1182/blood.V118.21.1712.1712

Published: 2011

Journal Articles

Hematopoietic Stem Cell Transplantation for Myelodysplastic Syndrome and Chronic Myelomonocytic Leukemia In Patients up to Age 75: Comparison of Survival In Patients with An Available Donor Compared to Patients without a Donor

Teresa Field, MD, PhD, Janelle Perkins, PharmD, Taiga Nishihori, MD, Joseph Pidala, Hugo F. Fernandez, MD, Marcie Tomblyn, MD, MS, Mohamed Kharfan-Dabaja, MD, Lia Perez, MD, Jeffrey E. Lancet, MD, Rami S. Komrokji, MD, Jose-Leonel ochoa-Bayona, M.D., Melissa Alsina, MD, Ernesto Ayala, MD, Jongphil Kim, Alan F. List, Claudio Anasetti, MD

Blood (2010) 116 (21): 2381.

https://doi.org/10.1182/blood.V116.21.2381.2381

Published: 2010

Journal Articles

Prospective Trial of Pre-Transplant 5-Azacitidine on Hematopoietic Cell Transplantation Outcomes for Myelodysplastic Syndrome and CMML

Teresa Field, MD, PhD, Janelle Perkins, PharmD, Taiga Nishihori, MD, Joseph Pidala, Hugo F. Fernandez, MD, Marcie Tomblyn, MD, MS, Mohamed Kharfan-Dabaja, MD, Lia Perez, MD, Rami S. Komrokji, MD, Jeffrey E. Lancet, MD, Jongphil Kim, Ernesto Ayala, MD, Melissa Alsina, MD, Jose-Leonel ochoa-Bayona, M.D., Alan F. List, Claudio Anasetti, MD

Blood (2010) 116 (21): 1333.

https://doi.org/10.1182/blood.V116.21.1333.1333

Published: 2010

Journal Articles

Maximally Tolerated Busulfan Area Under the Concentration-Time Curve (AUC) In Combination with Fludarabine as Conditioning Prior to Allogeneic Hematopoietic Cell Transplantation.

Janelle Perkins, PharmD, Teresa Field, MD, PhD, Jongphil Kim, PhD, Hugo F. Fernandez, MD, Lia Perez, MD, Ernesto Ayala, MD, Mohamed Kharfan-Dabaja, MD, Marcie Tomblyn, MD, MS, Daniel Sullivan, MD, Claudio Anasetti, MD

Blood (2010) 116 (21): 3499.

https://doi.org/10.1182/blood.V116.21.3499.3499

Published: 2010

Journal Articles

Targeted Intravenous Busulfan and Fludarabine Allogeneic Transplantation Conditioning in Acute Myeloid Leukemia.

Joseph A. Pidala, MD, Jongphil Kim, PhD, Claudio Anasetti, MD, Melissa Alsina, MD, Ernesto Ayala, MD, Teresa Field, MD, PhD, Mohamed A Kharfan-Dabaja, MD, Jose L Ochoa, MD, Lia Perez, MD, Janelle Perkins, PharmD, Marcie Tomblyn, MD, MS, Hugo F. Fernandez, MD

Blood (2009) 114 (22): 2290.

https://doi.org/10.1182/blood.V114.22.2290.2290

Published: 2009

Journal Articles

Evaluation of 243 Patients with Myelodysplastic Syndrome (MDS) Referred for Hematopoietic Cell Transplant (HCT) Including Donor Availability and HCT Outcomes.

Teresa Field, MD, PhD, Janelle Perkins, PharmD, Mohamed A Kharfan-Dabaja, MD, Hugo F. Fernandez, MD, Lia Perez, MD, J. Leonel Ochoa-Bayona, MD, Jeffrey E Lancet, MD, Rami S. Komrokji, MD, Melissa Alsina, MD, Ernesto Ayala, MD, Alan F List, MD, Claudio Anasetti, MD

Blood (2009) 114 (22): 3383.

https://doi.org/10.1182/blood.V114.22.3383.3383

Published: 2009

Journal Articles

Pharmacokinetically Targeted Intravenous Busulfan Combined with Fludarabine (BuFlu) as Conditioning Prior to Allogeneic Peripheral Blood Hematopoietic Cell Transplant: Pretransplant Predictors of Outcomes.

Janelle Perkins, PharmD, Jongphil Kim, PhD, Claudio Anasetti, MD, Mohamed A Kharfan-Dabaja, MD, Ernesto Ayala, MD, Lia Perez, MD, Hugo Fernandez, MD, Karen Fancher, PharmD, Cheryl Tate, PharmD, Teresa Field, MD

Blood (2009) 114 (22): 3347.

https://doi.org/10.1182/blood.V114.22.3347.3347

Published: 2009

NARROW

Impact of Obesity in Patients with Multiple Myeloma Receiving High-Dose Melphalan Followed By Autologous Hematopoietic Cell Transplantation

An International Multicenter Comparative Analysis of Tacrolimus Plus Sirolimus with or without Antithymocyte Globulin As Graft-Versus-Host Disease Prophylaxis in HLA-Mismatched Allogeneic Hematopoietic Cell Transplantation

TP53 and IDH2 Somatic Mutations Are Associated with Poor Outcomes Following Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndrome

Allogeneic Hematopoietic Stem Cell Transplantation (HCT) for Acute Myeloid Leukemia (AML) Not in First Remission

Sirolimus, Tacrolimus and Antithymocyte Globulin Are Associated with Improved Overall Survival When Compared to Methotrexate, Tacrolimus and Antithymocyte Globulin in Mismatched Unrelated Allogeneic Hematopoietic Cell Transplantation

Utility Of Revised International Prognostic Scoring System (R-IPSS) To Predict Outcome Of Myelodysplastic Syndromes (MDS) Patients After Allogeneic Hematopoietic Stem Cell Transplantation (AHSCT)

Evaluation Of Allogeneic Hematopoietic Cell Transplantation (HCT) Outcomes Of One Hundred Thirty-Two Patients With Myelodysplastic Syndrome (MDS) Or Chronic Myelomonocytic Leukemia (CMML) Up To Age Seventy-Five and The Effect Of Pre-Transplant 5-Azacitidine

Survival Advantage of Cell Therapy Over Cytotoxic Therapy Alone in Adult Patients with Relapsed AML After Allogeneic Hematopoietic Stem Cell Transplantation

Mycophenolate Mofetil versus Methotrexate for Prevention of Acute Graft-Versus-Host Disease: Results of a Systematic Review Limited to Prosepective Randomized Controlled Studies

Fludarabine and Targeted Busulfan Is Safe and Effective Conditioning Before Hematopoietic Stem Cell Transplantation in Adult Patients with Acute Lymphoblastic Leukemia in First Remission

Evaluation of a Risk-Based Algorithm for the Utilization of Plerixafor As Primary Mobilization of CD34+ Cells in Autologous Hematopoietic Cell Transplant Candidates,

Sirolimus/Tacrolimus Facilitates Preferential Recovery of Regulatory T Cells (Treg) After Allogeneic Hematopoietic Cell Transplantation (HCT), and Is More Effective Than Methotrexate/Tacrolimus in Preventing Grade II-IV Acute Graft Vs. Host Disease (GVHD) and Moderate to Severe Chronic Gvhd

Phase II Study of a Novel Reduced Toxicity Preparative Regimen for Hematopoietic Cell Allografting Combining Pentostatin (Nipent) and Targeted Doses of Intravenous Busulfan (Busulfex) with or without Rituximab (PB±R) Using a Novel Principle of CD4-Guided Immune Suppression

Azacitidine for Treatment of Therapy Related Myelodysplastic Syndrome

Hematopoietic Stem Cell Transplantation for Myelodysplastic Syndrome and Chronic Myelomonocytic Leukemia In Patients up to Age 75: Comparison of Survival In Patients with An Available Donor Compared to Patients without a Donor

Prospective Trial of Pre-Transplant 5-Azacitidine on Hematopoietic Cell Transplantation Outcomes for Myelodysplastic Syndrome and CMML

Maximally Tolerated Busulfan Area Under the Concentration-Time Curve (AUC) In Combination with Fludarabine as Conditioning Prior to Allogeneic Hematopoietic Cell Transplantation.

Targeted Intravenous Busulfan and Fludarabine Allogeneic Transplantation Conditioning in Acute Myeloid Leukemia.

Evaluation of 243 Patients with Myelodysplastic Syndrome (MDS) Referred for Hematopoietic Cell Transplant (HCT) Including Donor Availability and HCT Outcomes.

Pharmacokinetically Targeted Intravenous Busulfan Combined with Fludarabine (BuFlu) as Conditioning Prior to Allogeneic Peripheral Blood Hematopoietic Cell Transplant: Pretransplant Predictors of Outcomes.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only